Sanofi SA (SAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanofi SA (SAN) has a cash flow conversion efficiency ratio of 0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.92 Billion) by net assets (€71.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sanofi SA - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Sanofi SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sanofi SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prosus N.V.
AS:PRX
|
0.024x |
|
Blackstone Group Inc
NYSE:BX
|
0.000x |
|
Western Digital Corporation
NASDAQ:WDC
|
0.101x |
|
Canadian Natural Resources Ltd
NYSE:CNQ
|
0.085x |
|
Northrop Grumman Corporation
NYSE:NOC
|
0.234x |
|
MediaTek Inc
TW:2454
|
0.154x |
|
China Yangtze Power Co Ltd
SHG:600900
|
0.087x |
|
Bank of Montreal
NYSE:BMO
|
0.145x |
Annual Cash Flow Conversion Efficiency for Sanofi SA (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi SA from 1999 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €71.71 Billion | €10.92 Billion | 0.152x | +30.52% |
| 2024-12-31 | €77.86 Billion | €9.08 Billion | 0.117x | -15.46% |
| 2023-12-31 | €74.35 Billion | €10.26 Billion | 0.138x | -4.30% |
| 2022-12-31 | €73.02 Billion | €10.53 Billion | 0.144x | -5.42% |
| 2021-12-31 | €69.03 Billion | €10.52 Billion | 0.152x | +29.67% |
| 2020-12-31 | €63.37 Billion | €7.45 Billion | 0.118x | -10.28% |
| 2019-12-31 | €59.11 Billion | €7.74 Billion | 0.131x | +39.43% |
| 2018-12-31 | €59.03 Billion | €5.55 Billion | 0.094x | -25.84% |
| 2017-12-31 | €58.24 Billion | €7.38 Billion | 0.127x | -6.69% |
| 2016-12-31 | €57.72 Billion | €7.84 Billion | 0.136x | -11.39% |
| 2015-12-31 | €58.21 Billion | €8.92 Billion | 0.153x | +12.12% |
| 2014-12-31 | €56.27 Billion | €7.69 Billion | 0.137x | +12.09% |
| 2013-12-31 | €57.03 Billion | €6.95 Billion | 0.122x | -14.25% |
| 2012-12-31 | €57.47 Billion | €8.17 Billion | 0.142x | -13.99% |
| 2011-12-31 | €56.37 Billion | €9.32 Billion | 0.165x | -9.73% |
| 2010-12-31 | €53.29 Billion | €9.76 Billion | 0.183x | +4.20% |
| 2009-12-31 | €48.45 Billion | €8.52 Billion | 0.176x | -7.05% |
| 2008-12-31 | €45.07 Billion | €8.52 Billion | 0.189x | +18.82% |
| 2007-12-31 | €44.72 Billion | €7.12 Billion | 0.159x | +10.43% |
| 2006-12-31 | €45.82 Billion | €6.60 Billion | 0.144x | +4.42% |
| 2005-12-31 | €46.32 Billion | €6.39 Billion | 0.138x | +42.35% |
| 2004-12-31 | €41.52 Billion | €4.03 Billion | 0.097x | -72.86% |
| 2003-12-31 | €6.33 Billion | €2.26 Billion | 0.357x | +29.04% |
| 2002-12-31 | €6.06 Billion | €1.68 Billion | 0.277x | -11.84% |
| 2001-12-31 | €5.79 Billion | €1.82 Billion | 0.314x | +13.46% |
| 2000-12-31 | €4.33 Billion | €1.20 Billion | 0.277x | +20.71% |
| 1999-12-31 | €3.61 Billion | €828.00 Million | 0.229x | -- |
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more